Vanta Bioscience

22.12
-1.00
(-4.33%)
Market Cap
13.97 Cr
EPS
-3.67
PE Ratio
-
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
75.24
52 Week Low
22.53
PB Ratio
0.96
Debt to Equity
3.61
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
726.20
#1 29,232.24
60.81
#1 3,579.20
9.66
#1 510
17.58
58.60
578.50
13,881.37
35.61
2,665.90
12.77
337
11.03
56.70
113.67
2,478.84
-
32.80
#1 49.09
-105
6.46
43.47
1,004.50
2,232.28
36.91
322.30
0.22
41
112.87
49.32
92.53
217.86
-
769.70
-22.39
-59
17.26
78.00
6.69
98.97
-
67.20
-65.97
-120
#1 2,371.43
25.26
40.10
63.52
91.25
40.30
8.04
-1
120.00
41.23
16.80
26.30
#1 33.09
80.00
-3.26
2
-80.00
39.82
Vanta Bioscience
this company
22.12
#9 13.97
-
#9 9.80
#2 40.00
#6 -9
#9 -380.00
21.64
Growth Rate
Revenue Growth
40.00 %
Net Income Growth
-17.31 %
Cash Flow Change
525.40 %
ROE
20.22 %
ROCE
-24.77 %
EBITDA Margin (Avg.)
-158.91 %

Quarterly Financial Results

Quarterly Financials
Dec 2021
Mar 2022
Dec 2022
Mar 2023
Revenue
0
5
3
1
Expenses
0
2
3
2
EBITDA
0
2
-1
-1
Operating Profit %
0 %
46 %
-20 %
-206 %
Depreciation
0
1
1
0
Interest
0
1
3
1
Profit Before Tax
0
1
-4
-2
Tax
0
0
-2
-0
Net Profit
0
0
-3
-1
EPS in ₹
0.00
0.11
-4.06
0.00

Balance Sheet

Balance Sheet
2019
2020
2021
2022
2023
2024
Total Assets
39
49
70
81
85
85
Fixed Assets
18
21
29
36
57
54
Current Assets
17
20
20
15
15
17
Capital Work in Progress
4
7
19
29
11
13
Investments
2
0
0
0
0
0
Other Assets
16
21
21
17
17
19
Total Liabilities
39
49
70
81
85
85
Current Liabilities
3
10
15
18
18
23
Non Current Liabilities
13
14
29
34
48
50
Total Equity
23
25
26
29
19
13
Reserve & Surplus
16
17
18
18
11
9
Share Capital
6
6
6
6
6
6

Cash Flow

Cash Flow
2019
2020
2021
2022
2023
2024
Net Cash Flow
3
-3
3
-2
-0
0
Investing Activities
-6
-8
-22
-17
-6
-3
Operating Activities
-1
2
7
5
-1
3
Financing Activities
10
2
18
10
6
1

Share Holding

% Holding
Mar 2021
Sept 2021
Mar 2022
Sept 2022
Mar 2023
Sept 2023
Mar 2024
Sept 2024
Promoter
69.11 %
69.00 %
69.00 %
69.36 %
69.36 %
69.36 %
69.36 %
69.36 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
26.39 %
26.41 %
26.35 %
26.56 %
26.77 %
26.77 %
25.97 %
26.55 %
Others
4.50 %
4.59 %
4.65 %
4.08 %
3.87 %
3.87 %
4.67 %
4.09 %
No of Share Holders
361
412
409
393
394
388
418
424

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %

No dividends have been distributed by the company in the past 10 years

Corporate Action

Announcements

Closure of Trading Window1 day ago
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJan 07, 2025
Notice Of EGM To Be Held On 04.01.2025Dec 12, 2024
EGM On 04.01.2025Dec 07, 2024
Board Meeting Outcome for Outcome Of Board Meeting Held On 06.12.2024Dec 06, 2024
Board Meeting Intimation for Conversion Of Unsecured Loans Into Equity SharesDec 03, 2024
Unaudited Results For 30.09.2024Nov 14, 2024
Board Meeting Outcome for Outcome Of Board Meeting Held On 14.11.2024Nov 14, 2024
Board Meeting Intimation for Approval Of Un-Audited Financial Statements Of 30.09.2024 And Conversion Of Unsecured Loans Into Equity SharesNov 11, 2024
Reply To Clarification On Price Movement Sought By BSENov 07, 2024
Clarification sought from Vanta Bioscience LtdNov 06, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportOct 01, 2024
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 30, 2024
Closure of Trading WindowSep 28, 2024
Submission Of Revised Financial Statements For The Period Ended 31.03.2024 Pursuant To Query From BSE Regarding Bifurcation Of Trade PayablesSep 19, 2024
Reg. 34 (1) Annual Report.Sep 06, 2024
AGM On 30.09.2024Sep 06, 2024
Board Meeting Outcome for Outcome Of Board Meeting Held On 06.09.2024 - 8Th Annual General Meeting To Be Held On 30.09.2024Sep 06, 2024
Intimation Of Submission Of Application To BSE For Reclassification From 'Promoter' Category To 'Public' CategoryAug 18, 2024
Regulation 30 - Submission Of Resignation Letters Of Directors Dated 19.07.2024Jul 24, 2024
Approval Of Board For Reclassification Of 2 Promoters To Public CategoryJul 20, 2024
Approval Of Board For Reclassification Of 2 Promoters To Public CategoryJul 20, 2024
Results For The Period Ended 31.03.2024Jul 19, 2024
Board Meeting Outcome for Outcome Of Board Meeting Held On 19.07.2024Jul 19, 2024
Board Meeting Intimation for Intimation Regarding Postponement Of Board Meeting To 19.07.2024 For Approval Of Financial Results Of The CompanyJul 17, 2024
Board Meeting Intimation for Approval Of Financial Results For The Half Year And Year Ended 31.03.2024Jul 10, 2024
Compliance Certificate Under Regulation 40(9)Apr 21, 2024
Reg. 34 (1) Annual Report.Apr 21, 2024
Compliance Certificate Under Regulation 7(3)Apr 21, 2024
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderApr 02, 2024
Appointment of Company Secretary and Compliance OfficerApr 01, 2024
Closure of Trading WindowMar 30, 2024
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderDec 01, 2023
Change In Designation Of Dr. Vyasmurti Madhavrao Shingatgeri (DIN 07728757) From Whole Time Director To Non-Executive Director W.E.F 14.11.2023.Nov 14, 2023
Board Meeting Outcome for Outcome Of Board Meeting Held On 14.11.2023Nov 14, 2023
Board Meeting Intimation for Approval Of Unaudited Financial Statements For The Period Ended 30.09.2023Nov 08, 2023
Corporate Insolvency Resolution Process (CIRP)-Updates - Corporate Insolvency Resolution Process (CIRP)Nov 02, 2023
Reg. 34 (1) Annual Report.Oct 16, 2023
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportOct 04, 2023
Shareholder Meeting / Postal Ballot-Outcome of AGMOct 01, 2023
Closure of Trading WindowSep 30, 2023
AGM On 30.09.2023Sep 06, 2023
Financial Results For The Half Year And Year Ended 31.03.2023Aug 10, 2023
Financial Results For The Period Ended 30.09.2022Aug 10, 2023
Board Meeting Outcome for Outcome Of Board Meeting Held On 10.08.2023Aug 10, 2023
Board Meeting Intimation for Approval Of Financial Results Of The Company For The Half Year Ended 30.09.2022 And Year Ended 31.03.2023Aug 04, 2023
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerJul 10, 2023
Announcement under Regulation 30 (LODR)-Meeting UpdatesMay 30, 2023
Board Meeting Intimation for Approval Of Financial Statements For The Period Ended 30.09.2022 And 31.03.2023May 22, 2023
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 30, 2023

Technical Indicators

RSI(14)
Neutral
21.64
ATR(14)
Volatile
1.63
STOCH(9,6)
Oversold
5.54
STOCH RSI(14)
Oversold
0.00
MACD(12,26)
Bearish
-0.39
ADX(14)
Strong Trend
31.22
UO(9)
Bullish
27.90
ROC(12)
Downtrend And Accelerating
-27.12
WillR(14)
Oversold
-98.48